You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Navigating the New Treatment Landscape in Inflammatory Bowel Disease

  • Authors: Raymond K. Cross, MD, MS, AGAF; Sandra M. Quezada, MD, MS, AGAF; Jessica R. Allegretti, MD, MPH, AGAF, FACG
  • CME Released: 5/31/2023
  • Valid for credit through: 5/31/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, obstetricians/gynecologists, physician assistants, nurses, and nurse practitioners.

The goal of this activity is for learners to be better able to incorporate new targeted treatments for IBD into practice, including individualizing treatment.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanisms of action of new targeted treatments for IBD
    • Clinical data on new targeted IBD treatments
  • Have greater competence related to
    • Recommending evidence-based IBD treatments that consider patients’ comorbid conditions
  • Demonstrate greater confidence in their ability to
    • Incorporate new targeted agents for IBD into treatment strategies


Disclosures

The AGA Institute requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Raymond K. Cross, MD, MS, AGAF

    Professor of Medicine
    Division of Gastroenterology and Hepatology
    Director, Inflammatory Bowel Disease Program
    Director, Digestive Health Center
    University of Maryland School of Medicine
    Baltimore, Maryland

    Disclosures

    Raymond K. Cross, MD, MS, AGAF, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Adiso Therapeutics; Bristol-Myers Squibb; Frensenius Kabi; Fzata, Inc.; Janssen Pharmaceuticals; Magellan Health; Pfizer, Inc.; Samsung Bioepis; Sebela Pharmaceuticals Inc.; Takeda Pharmaceuticals North America, Inc.
    Research funding from: Janssen Pharmaceuticals (pending)

  • Sandra M. Quezada, MD, MS, AGAF

    Associate Professor of Medicine
    Division of Gastroenterology and Hepatology
    Associate Dean for Medical School Admissions
    Associate Dean for Faculty Diversity and Inclusion
    University of Maryland School of Medicine
    Baltimore, Maryland

    Disclosures

    Sandra M. Quezada, MD, MS, AGAF, has the following relevant financial relationships:
    Consultant or advisor for: ​Janssen Pharmaceuticals ​

  • Jessica R. Allegretti, MD, MPH, AGAF, FACG

    Associate Professor of Medicine
    Harvard Medical School
    Director, Crohn’s and Colitis Center
    Director, Fecal Microbiota Transplant Program
    Brigham & Women’s Hospital
    Boston, Massachusetts

    Disclosures

    Jessica R. Allegretti, MD, MPH, AGAF, FACG, has the following relevant financial relationships: 
    Consultant or advisor for: AbbVie Inc.; Bristol-Myers Squibb Company; Finch Therapeutics; Janssen Pharmaceuticals; Iterative Scopes; Lilly; Merck & Co., Inc.; Pfizer Inc.; Seres
    Speaker or member of speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company
    Research funding from: Janssen Pharmaceuticals; Merck & Co., Inc.; Pfizer Inc.
    Contracted researcher for: Artugen Therapeutics; Amgen Inc.; Finch Therapeutics; Janssen Pharmaceuticals; Pfizer Inc.

Editor

  • Roderick Smith, MS

    Senior Medical Education Director, Medscape, LLC

    Disclosures

    Roderick Smith, MS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and American Gastroenterological Association.

American Gastroenterological Association​

    For Physicians

  • The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The AGA Institute designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Navigating the New Treatment Landscape in Inflammatory Bowel Disease

Authors: Raymond K. Cross, MD, MS, AGAF; Sandra M. Quezada, MD, MS, AGAF; Jessica R. Allegretti, MD, MPH, AGAF, FACGFaculty and Disclosures

CME Released: 5/31/2023

Valid for credit through: 5/31/2024, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is for learners to be better able to incorporate new targeted treatments for IBD into practice, including individualizing treatment.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print